Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2019 Feb 14

PMID 30756315

Citations 15

Authors

Matthew C Hernandez

John R Bergquist

Jennifer L Leiting

Tommy Ivanics

Lin Yang

Rory L Smoot

David M Nagorney

Mark J Truty

Affiliations

Soon will be listed here.

Abstract

Background: Patient-derived xenografts (PDX) are clinically relevant human cancer models that can be used to guide individualized medicine. We aimed to generate PDX models from clinically obtained biopsy specimens (surgical or image-guided) hypothesizing that low volume biopsy specimens could provide sufficient viable tissue to successfully engraft PDX models from patients with unresectable or metastatic disease.

Materials And Methods: We maintain a prospective high volume gastrointestinal malignancy PDX program. With informed consent and institutional approval, biopsy specimens (surgical or image-guided) were obtained from patients with unresectable or metastatic tumors: pancreatic adenocarcinoma (PDAC), cholangiocarcinoma, gastric and gallbladder carcinoma. Biopsies were implanted into immunodeficient mice. Tumor growth was monitored, viable tumor was passed into subsequent generations, and histopathology was confirmed.

Results: In this study, biopsy specimens from 29 patients were used for PDX engraftment. Successful PDX engraftment was variable with highest engraftment rates in gastric and gallbladder carcinoma specimens (100%) compared to engraftment rates of 33% and 29% in PDAC and cholangiocarcinoma respectively. PDX models created from metastasis biopsies compared to unresectable primary tumor tissue demonstrated higher engraftment rates (69% versus 15.4%, p = 0.001). PDX models demonstrated higher engraftment rates when biopsies were obtained during surgical operations (n = 15) compared to image-guided (n = 14) (73% versus 14%, p = 0.003). Patient age, pretreatment status, or ischemic time was not different between biopsy methods.

Conclusions: PDX models can be successfully created from clinical biopsy specimens in patients with metastatic or unresectable GI cancers. The use of clinical biopsy specimens for PDX engraftment can expand the repertoire of stage-specific PDX models for downstream basic/translational research.

Citing Articles

Factors associated with engraftment success of patient-derived xenografts of breast cancer.

Lee J, Lee G, Park H, Jeong B, Gong G, Jeong J Breast Cancer Res. 2024; 26(1):49.

PMID: 38515107 PMC: 10956311. DOI: 10.1186/s13058-024-01794-w.

Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts).

Hernandez Guerrero T, Banos N, Del Puerto Nevado L, Mahillo-Fernandez I, Doger De-Speville B, Calvo E Cancers (Basel). 2023; 15(22).

PMID: 38001663 PMC: 10670531. DOI: 10.3390/cancers15225402.

Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice.

Zeng M, Ruan Z, Tang J, Liu M, Hu C, Fan P Cancer Cell Int. 2023; 23(1):120.

PMID: 37344821 PMC: 10283277. DOI: 10.1186/s12935-023-02953-3.

Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.

Li M, Zhou X, Wang W, Ji B, Shao Y, Du Q J Clin Transl Hepatol. 2022; 10(4):700-710.

PMID: 36062286 PMC: 9396327. DOI: 10.14218/JCTH.2021.00374.

Patient-Derived Xenograft: A More Standard "Avatar" Model in Preclinical Studies of Gastric Cancer.

Zeng M, Pi C, Li K, Sheng L, Zuo Y, Yuan J Front Oncol. 2022; 12:898563.

PMID: 35664756 PMC: 9161630. DOI: 10.3389/fonc.2022.898563.

References

Johnson J, Decker S, Zaharevitz D, Rubinstein L, Venditti J, SCHEPARTZ S . Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001; 84(10):1424-31. PMC: 2363645. DOI: 10.1054/bjoc.2001.1796. View

Bagatell R, Khan O, Taylor C, Akinaga S, Whitesell L . Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin Cancer Res. 2001; 7(7):2076-84. View

Khan S, Taylor-Robinson S, Toledano M, Beck A, Elliott P, Thomas H . Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002; 37(6):806-13. DOI: 10.1016/s0168-8278(02)00297-0. View

Gatto M, Bragazzi M, Semeraro R, Napoli C, Gentile R, Torrice A . Cholangiocarcinoma: update and future perspectives. Dig Liver Dis. 2010; 42(4):253-60. DOI: 10.1016/j.dld.2009.12.008. View

Gillen S, Schuster T, Zum Buschenfelde C, Friess H, Kleeff J . Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010; 7(4):e1000267. PMC: 2857873. DOI: 10.1371/journal.pmed.1000267. View

Singh P, Srinivasan R, Wig J . Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment. Pancreas. 2011; 40(5):644-52. DOI: 10.1097/MPA.0b013e31821ff741. View

Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

Chang Q, Foltz W, Chaudary N, Hill R, Hedley D . Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. Int J Cancer. 2013; 133(1):225-34. DOI: 10.1002/ijc.28006. View

Murphy S, Hart S, Lima J, Kipp B, Klebig M, Winters J . Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology. 2013; 145(5):1098-1109.e1. PMC: 3926442. DOI: 10.1053/j.gastro.2013.07.049. View

10.

Puig I, Chicote I, Tenbaum S, Arques O, Herance J, Gispert J . A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells. Clin Cancer Res. 2013; 19(24):6787-801. DOI: 10.1158/1078-0432.CCR-12-1740. View

11.

Rahib L, Smith B, Aizenberg R, Rosenzweig A, Fleshman J, Matrisian L . Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11):2913-21. DOI: 10.1158/0008-5472.CAN-14-0155. View

12.

Hidalgo M, Amant F, Biankin A, Budinska E, Byrne A, Caldas C . Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014; 4(9):998-1013. PMC: 4167608. DOI: 10.1158/2159-8290.CD-14-0001. View

13.

Boj S, Hwang C, Baker L, Chio I, Engle D, Corbo V . Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015; 160(1-2):324-38. PMC: 4334572. DOI: 10.1016/j.cell.2014.12.021. View

14.

Delitto D, Pham K, Vlada A, Sarosi G, Thomas R, Behrns K . Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol. 2015; 185(5):1297-303. PMC: 4419203. DOI: 10.1016/j.ajpath.2015.01.016. View

15.

Nakajima T, Geddie W, Anayama T, Ko H, da Cunha Santos G, Boerner S . Patient-derived tumor xenograft models established from samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration. Lung Cancer. 2015; 89(2):110-4. DOI: 10.1016/j.lungcan.2015.05.018. View

16.

Gandara D, Lara Jr P, Mack P . Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. J Clin Oncol. 2015; 33(26):2839-40. DOI: 10.1200/JCO.2015.61.9692. View

17.

Brandi G, Venturi M, Pantaleo M, Ercolani G . Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Dig Liver Dis. 2016; 48(3):231-41. DOI: 10.1016/j.dld.2015.11.017. View

18.

Francis O, Milford T, Beldiman C, Payne K . Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia. J Investig Med. 2016; 64(3):740-4. PMC: 5154753. DOI: 10.1136/jim-2016-000076. View

19.

Allaway R, Fischer D, De Abreu F, Gardner T, Gordon S, Barth R . Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget. 2016; 7(13):17087-102. PMC: 4941373. DOI: 10.18632/oncotarget.7718. View

20.

Seidensticker R, Seidensticker M, Doegen K, Mohnike K, Schutte K, Stubs P . Extensive Use of Interventional Therapies Improves Survival in Unresectable or Recurrent Intrahepatic Cholangiocarcinoma. Gastroenterol Res Pract. 2016; 2016:8732521. PMC: 4758109. DOI: 10.1155/2016/8732521. View